ÂÜÀòÂÒÂ×

Marco has more than 35 years of experience in various international executive roles in the biopharma industry. His most recent position was Chief Operating Officer at Nordic Nanovector, a public clinical stage company listed on the Oslo Stock Exchange (2014-2021). Prior to joining Nordic Nanovector, Marco served as SVP, Chief Commercial Officer at Shionogi Ltd (2012-2014). From 2009 to 2012, he was Executive Director, Oncology Franchise Head for Amgen International, after leading (2005-2008) the Italian affiliate as Managing Director. Prior to Amgen, Marco held national and global R&D and business roles at Novartis, Searle-Monsanto and Pharmacia. Marco is Board Chairperson of Phi Pharma, a private Switzerland-based biotech company focusing on the development of peptide drug conjugates. Marco holds a medical degree from the University of Milan and an MBA from Fondazone IDI/Assolombarda. Marco is an Italian citizen, and he resides in Switzerland.